Clinical trial
Differences in Metabolic and Cardiovascular Effects of Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes
NCT00609856 is registered in ClinicalTrials.gov with Skane University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Differences in Metabolic and Cardiovascular Effects of Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes
- Lead sponsor
- Skane University Hospital
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 30, 2004
- Completion date
- December 31, 2006
- Enrollment
- 36 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
secondary drug failure, type 2 diabetes
Lead sponsor's other trials
Skane University Hospital, most recent start first.
+67 more trials See the organization page
Similar trials
Same condition (Diabetes Mellitus, Type 2) and phase, most recent start first.
+1,179 more trials See the condition page